View of Cost-Effectiveness of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Infants | Canadian Journal of Health Technologies

← Cost-Effectiveness of Nirsevimab for the Prevention of Respiratory Syncytial Virus Infection in Infants